$55.63 Million in Sales Expected for Cardiovascular Systems Inc (CSII) This Quarter
Brokerages forecast that Cardiovascular Systems Inc (NASDAQ:CSII) will report sales of $55.63 million for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Cardiovascular Systems’ earnings. The lowest sales estimate is $55.30 million and the highest is $55.90 million. Cardiovascular Systems posted sales of $52.14 million in the same quarter last year, which suggests a positive year over year growth rate of 6.7%. The firm is expected to report its next quarterly earnings results on Wednesday, May 2nd.
On average, analysts expect that Cardiovascular Systems will report full year sales of $55.63 million for the current year, with estimates ranging from $215.40 million to $217.20 million. For the next fiscal year, analysts forecast that the business will report sales of $242.45 million per share, with estimates ranging from $235.24 million to $251.24 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that cover Cardiovascular Systems.
Cardiovascular Systems (NASDAQ:CSII) last posted its earnings results on Wednesday, February 7th. The medical device company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.03. The firm had revenue of $52.63 million for the quarter, compared to analyst estimates of $53.39 million. Cardiovascular Systems had a negative return on equity of 0.50% and a negative net margin of 1.62%. Cardiovascular Systems’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same period last year, the company earned $0.03 earnings per share.
Shares of Cardiovascular Systems (NASDAQ CSII) opened at $24.11 on Friday. The company has a market capitalization of $821.68, a PE ratio of -241.10 and a beta of 2.26. Cardiovascular Systems has a 1-year low of $20.58 and a 1-year high of $33.11. The company has a current ratio of 4.65, a quick ratio of 4.13 and a debt-to-equity ratio of 0.17.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Teacher Retirement System of Texas purchased a new position in shares of Cardiovascular Systems in the fourth quarter valued at approximately $273,000. Trexquant Investment LP purchased a new position in shares of Cardiovascular Systems in the third quarter valued at approximately $276,000. US Bancorp DE lifted its position in shares of Cardiovascular Systems by 51.7% in the fourth quarter. US Bancorp DE now owns 13,208 shares of the medical device company’s stock valued at $313,000 after acquiring an additional 4,500 shares in the last quarter. MetLife Investment Advisors LLC purchased a new position in shares of Cardiovascular Systems in the fourth quarter valued at approximately $354,000. Finally, Voya Investment Management LLC lifted its position in shares of Cardiovascular Systems by 7.7% in the second quarter. Voya Investment Management LLC now owns 15,836 shares of the medical device company’s stock valued at $510,000 after acquiring an additional 1,127 shares in the last quarter. 79.18% of the stock is currently owned by institutional investors.
Cardiovascular Systems Company Profile
Cardiovascular Systems, Inc is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company develops an orbital atherectomy technology for both peripheral and coronary commercial applications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cardiovascular Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiovascular Systems and related companies with MarketBeat.com's FREE daily email newsletter.